Silodosin efficacy in patients with severe lower urinary tract symptoms due to BPH

Α1A selective alpha blockers are more tolerable to patients with benign prostatic hyperplasia (BPH), than non-selective ones. This is especially important consideration in patients with the risk of adverse cardio-vascular effects. One of the new αlA selective alpha blockers is silodosin. There is enough evidence, related to the efficacy and safety of silodosin in patients with lower urinary tract symptoms (LUTS) due to BPH. Aim of the observation: evaluation of the efficacy of silodosin in patients with severe LUTS due to BPH. We have included 30 patients with age of 47-75 years with LUTS due to BPH, which received silodosin 8 mg once a day. Observation included 3 visits: V0 -screening, V1 - 5 days after initiation of treatment, V2 - 60 days after treatment initiation. During every visit patients fulfilled the questionnaire IPSS/QoL, underwent uroflowmetry with the estimation of postvoid residual volume (PVR). Efficacy criteria were: changes in IPSS/QoL, Qmax and PVR dynamics. The results showed that silodosin have significantly improved main clinical and urodynamic parameters (IPSS, QoL, Qmax, Qave, Vcomp, Vres), showing rapid onset of the effect. Prominent improvement was observed with regard to IPSS (53.3%) and Qmax (73.3%). It was shown that patients with moderate LUTS demonstrated better improvement while being on silodosin. Patients with IPSS 10 ml/sec could demonstrate a good response to silodosin.